The short answer
GIP is released by K cells and GLP-1 by L cells. More than 80% of labelled cells produce only one of the two, but the populations are transcriptomically close and share their principal glucose-sensing mechanism, differing mainly in other lipid sensors.
Key facts
- K cell hormone
- GIP
- L cell hormone
- GLP-1
- Cells producing only one hormone
- More than 80% in labelled models
- Shared glucose sensor
- SGLT1, in both
- Shared fatty acid receptors
- FFAR1 (GPR40) and FFAR4 (GPR120)
- Documented for GLP-1 specifically
- GPR119, FFAR2, FFAR3
- Selectively inhibits GIP
- Endocannabinoid receptor type 1 agonists
- Implication drawn by the authors
- The two secretions might be modulated differentially
Why the distinction is usually drawn too sharply
The standard account presents K cells and L cells as separate populations in separate parts of the gut releasing separate hormones: K cells proximally releasing GIP, L cells distally releasing GLP-1. The picture Reimann and Gribble describe is messier and more interesting. In human tissue and in murine models expressing fluorescent markers under the control of the two hormone promoters, the majority of labelled cells (more than 80%) do produce only one of the two hormones, so the distinction is real. But transcriptomic analysis shows a close relationship between small intestinal K and L cells, and the remainder produce both.
They sense glucose the same way
The glucose-sensing mechanism appears similar in both cell types, with a predominant role for electrogenic uptake through SGLT1 in each. That is a substantial shared component: the stimulus that most obviously accompanies a meal is read by the same machinery in both populations. It also means that anything acting on intestinal glucose handling engages both incretin-secreting populations rather than one, which is worth knowing when reasoning about interventions at that level.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
And they share the main fat receptors
Both cell types produce FFAR1 (GPR40) and FFAR4 (GPR120), the long-chain fatty acid receptors. So the two principal macronutrient signals, glucose and long-chain fat, are detected by the same sensors in both populations. On the sensing side, K cells and L cells are more alike than the tidy proximal-versus-distal story suggests.
Where they differ, and why it is the interesting part
The differences sit in the other lipid-sensing receptors. GPR119 and FFAR2/3 have clearly documented roles in GLP-1 secretion, while agonists for the endocannabinoid receptor type 1 have been found to show largely selective inhibition of GIP secretion. So there are handles that move one hormone and not the other, in both directions. The authors conclude that although the populations overlap and share key nutrient-sensing mechanisms, subtle differences might be exploited to differentially modulate GIP or GLP-1 secretion.
Why that matters given how this field has gone
The most unresolved question in incretin pharmacology is what to do about GIP. Tirzepatide agonises the GIP receptor alongside GLP-1 and works extremely well. Other programmes have pursued GIP receptor antagonism alongside GLP-1 agonism and also report substantial effects. The debate is conducted almost entirely at the level of receptors. This work points out that the same question exists one step earlier, at the level of secretion: it may be possible to change how much of each incretin is released, not only what happens when it binds. Nothing has been made of that observation commercially, and it remains a stated possibility rather than a demonstrated strategy.
What this does not change
The therapeutic agents in use are receptor agonists, not secretagogues, and everything about their exposure profile differs from endogenous secretion. Understanding that K and L cells are close relatives explains the physiology and does not alter how the drugs work. None of the compounds discussed here is supplied on this site, and licensed incretin medicines are prescription products that research material is not a version of.
Quick reference
| K cell | L cell | |
|---|---|---|
| Hormone | GIP | GLP-1 |
| Glucose sensing | SGLT1, electrogenic | SGLT1, electrogenic |
| FFAR1 / FFAR4 | Present | Present |
| GPR119 | Less documented | Documented role in secretion |
| FFAR2 / FFAR3 | Less documented | Documented role in secretion |
| CB1 agonists | Selectively inhibit secretion | Not the main target |
Frequently asked questions
Do any cells make both GIP and GLP-1?
Yes. The figure quoted is that more than 80% of labelled cells make only one, which leaves a minority making both. Those dual-positive cells are part of why the two populations look transcriptomically close.
Is GIP secreted more proximally than GLP-1?
The classical distribution places K cells more proximally and L cells more distally, and the density gradients are real. The point of this work is that the sensing machinery is largely shared regardless of where the cells sit.
Could a drug raise GLP-1 without raising GIP?
The receptors that differ between the cell types make it conceivable, and that is what the review suggests. Conceivable is not demonstrated, and no such agent is licensed.
Does this affect how tirzepatide should be understood?
Not directly: tirzepatide acts at the receptors, not on secretion. It is relevant context for the wider argument about whether GIP signalling should be increased or blocked, because it shows the secretion side is a separate and largely unexplored lever.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedReimann F, Gribble FM, Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion - J Diabetes Investig 2016 (PMID 27186350)pubmed.ncbi.nlm.nih.gov
- PubMedParker HE et al., Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion - Br J Pharmacol 2012 (PMID 21718300)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Gap Between a Meal Response and a DrugNative GLP-1 is released in bursts and destroyed within minutes. An agonist is present continuously for a week or more. The difference is not one of degree.
- The Randomisation Ratio Decides What a Trial Can SayTwo trials of the same combination allocated participants very differently. One can measure the components' contribution properly and the other cannot.
- A p-Value of 0.0035 and an Effect of 0.16A large trial can detect a difference far below the size that would matter to anyone. Statistical significance and clinical importance are separate questions.
- The Obesity Drug Pipeline in 2026Every major incretin and amylin compound in development in 2026: retatrutide, CagriSema, amycretin, survodutide, mazdutide and orforglipron, with trial data.
- What Is CagriSema? Cagrilintide Plus SemaglutideCagriSema combines cagrilintide and semaglutide at 2.4 mg each. REDEFINE 1 reported 22.7% mean reduction at 68 weeks - and 20.4% on the other estimand.